Trial Profile

A Pivotal Phase III Clinical Trial to Evaluate ILC (Inhaled Lipid-Cisplatin) for Patients with Small Cell Lung Cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 May 2021 According to an Eleison Pharmaceuticals media release, the companys ILC (Inhaled Lipid-Cisplatin) program is expected to begin this potentially pivotal phase III clinical trial in 2021 or 2022.
21 Dec 2020 New trial record
11 Dec 2020 According to an Eleison Pharmaceuticals media release, the companys ILC (Inhaled Lipid-Cisplatin) program is expected to begin a potentially pivotal phase II clinical trial in 2021 for patients with small cell lung cancer. Eleison is pleased to announce it recently received approval from the National Medical Products Administration (formerly known as the China FDA) to commence enrollment in China for this lung cancer study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com